Bio-Techne is selling off in pre-market trading despite the company reporting a Q1 fiscal 2027 earnings beat on November 9, where adjusted EPS of 44 cents surpassed estimates by 10% and revenues grew 5% to $299.7 million.
While shareholders recently approved the merger with Merck KGaA, the stock is currently facing downward pressure that is not explained by any new company-specific filings or disclosures since that report. The move appears decoupled from its immediate peers, as Thermo Fisher, Agilent, and Revvity all saw only fractional